Ticker LaunchIPO · CALTX
Calliditas Therapeutics AB
Calliditas Therapeutics AB (CALTX) priced its initial public offering on Jun 8, 2020 at $19.50 per ADS, and listed on Nasdaq Global Select. Goodwin Procter advised the company and Cooley and Baker McKenzie advised the underwriters.
Calliditas Therapeutics AB is a clinical-stage biopharmaceutical company developing treatments for orphan renal and hepatic diseases. Its lead candidate, Nefecon, is an oral formulation of budesonide for IgA nephropathy, an autoimmune kidney disease with no approved treatments.
- Status
- IPO
- Ticker
- CALTX
- Exchange
- Nasdaq Global Select
- Priced
- Jun 8, 2020
- IPO price
- $19.50 per ADS
- First filed
- May 14, 2020
- Company counsel
- Goodwin Procter
- Underwriters' counsel
- Cooley and Baker McKenzie
- Sector
- Biotech & pharma
- Country / state
- Sweden
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed May 14, 2020
- Latest amendment Jun 4, 2020
- Final prospectus (424B4) Jun 8, 2020
- All filings on EDGAR CIK 1795579
Other Biotech & pharma IPOs in 2020
- Avidity Biosciences, Inc.RNA · Jun 12, 2020 · $259.2M
- Generation Bio Co.Jun 12, 2020 · $200M
- Lantern Pharma Inc.LTRN · Jun 12, 2020 · $26.2M
- Legend Biotech CorpLEGN · Jun 8, 2020 · $423.8M
- Applied Molecular Transport Inc.AMTI · Jun 5, 2020 · $154M
- Pliant Therapeutics, Inc.PLRX · Jun 3, 2020 · $144M